Pearson Syndrome Treatment & Management
- Author: Zora R Rogers, MD; Chief Editor: Hassan M Yaish, MD more...
No specific therapy is available for individuals with Pearson syndrome or other mitochondrial cytopathies. Awareness of possible complications and early intervention may prevent death and minimize morbidity.
Red blood cell transfusions are often needed to manage the macrocytic anemia, and patients may be dependent on transfusions. Erythropoietin has been tried to decrease the frequency of transfusions.
Pancreatic enzyme replacement is needed for patients with malabsorption due to exocrine pancreatic insufficiency. Supplementation with fat-soluble vitamins (ADEK) may also be needed.
Although without controlled evidence of benefit, many clinicians offer supplementation with coenzyme Q and additional supplementation with carnitine and riboflavin.
In neutropenic patients, fever higher than 101.5 º F should be evaluated promptly. Parenteral antibiotics should be administered after blood is obtained. Splenic atrophy may also increase the risk of bacteremia due to encapsulated organism. Granulocyte colony-stimulating factor (G-CSF) has been used in some patients to ameliorate severe neutropenia.
Manage intermittent metabolic crises with hydration, correction of electrolyte abnormalities, correction of acidosis, and a search for underlying causes (eg, infection). Seek evidence of concomitant hepatic failure. Chronic bicarbonate supplementation and dichloroacetic acid have been used to treat persistent metabolic acidosis.
Patients may have hypothyroidism, hypoparathyroidism, diabetes mellitus, or growth hormone deficiency. These conditions should be screened for and treated, if present.
Stem cell transplantation has been reported in only one individual with Pearson syndrome. Pearson syndrome is a multisystem disorder, thus, transplantation can only correct the hematologic manifestations of the disorder and cannot correct the dysfunction of other systems. Transplantation may be associated with unique or greater than expected toxicities as well.
No specific surgical management is needed for patients with Pearson syndrome.
Some patients may benefit from an indwelling venous catheter to facilitate frequent transfusions or infusions.
Patient should be seen in consultation by and managed in collaboration with an expert in metabolism and genetics in addition to a hematologist.
If endocrine, renal, or cardiac complications are present, appropriate specialists should be involved in comanagement.
No dietary restrictions or modifications are required.
No specific restrictions to activity are required.
Patients with neuromuscular manifestations may require appropriate support.
Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr. 1979 Dec. 95(6):976-84. [Medline].
Blaw ME, Mize CE. Juvenile Pearson syndrome. J Child Neurol. 1990 Jul. 5(3):187-90. [Medline].
Rotig A, Bourgeron T, Chretien D, et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet. 1995 Aug. 4(8):1327-30. [Medline].
Rotig A, Cormier V, Koll F, et al. Site-specific deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome. Genomics. 1991 Jun. 10(2):502-4. [Medline].
Rotig A, Cormier V, Blanche S, et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest. 1990 Nov. 86(5):1601-8. [Medline].
Kerr DS. Protean manifestations of mitochondrial diseases: a minireview. J Pediatr Hematol Oncol. 1997 Jul-Aug. 19(4):279-86. [Medline].
De Vivo DC. The expanding clinical spectrum of mitochondrial diseases. Brain Dev. 1993 Jan-Feb. 15(1):1-22. [Medline].
Harding AE, Hammans SR. Deletions of the mitochondrial genome. J Inherit Metab Dis. 1992. 15(4):480-6. [Medline].
Williams TB, Daniels M, Puthenveetil G, Chang R, Wang RY, Abdenur JE. Pearson syndrome: unique endocrine manifestations including neonatal diabetes and adrenal insufficiency. Mol Genet Metab. 2012 May. 106(1):104-7. [Medline].
Krauch G, Wilichowski E, Schmidt KG, Mayatepek E. Pearson marrow-pancreas syndrome with worsening cardiac function caused by pleiotropic rearrangement of mitochondrial DNA. Am J Med Genet. 2002 Jun 1. 110(1):57-61. [Medline].
Muraki K, Nishimura S, Goto Y, et al. The association between haematological manifestation and mtDNA deletions in Pearson syndrome. J Inherit Metab Dis. 1997 Sep. 20(5):697-703. [Medline].
Seneca S, De Meirleir L, De Schepper J, et al. Pearson marrow pancreas syndrome: a molecular study and clinical management. Clin Genet. 1997 May. 51(5):338-42. [Medline].
Stoddard RA, McCurnin DC, Shultenover SJ, et al. Syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction presenting in the neonate. J Pediatr. 1981 Aug. 99(2):259-61. [Medline].
Superti-Furga A, Schoenle E, Tuchschmid P, et al. Pearson bone marrow-pancreas syndrome with insulin-dependent diabetes, progressive renal tubulopathy, organic aciduria and elevated fetal haemoglobin caused by deletion and duplication of mitochondrial DNA. Eur J Pediatr. 1993 Jan. 152(1):44-50. [Medline].
Manea EM, Leverger G, Bellmann F, et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J Pediatr Hematol Oncol. 2009 Dec. 31(12):947-51. [Medline].
McShane MA, Hammans SR, Sweeney M, et al. Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am J Hum Genet. 1991 Jan. 48(1):39-42. [Medline].
Morel AS, Joris N, Meuli R, et al. Early neurological impairment and severe anemia in a newborn with Pearson syndrome. Eur J Pediatr. 2009 Mar. 168(3):311-5. [Medline].
Knerr I, Metzler M, Niemeyer CM, et al. Hematologic features and clinical course of an infant with Pearson syndrome caused by a novel deletion of mitochondrial DNA. J Pediatr Hematol Oncol. 2003 Dec. 25(12):948-51. [Medline].
Lee HF, Lee HJ, Chi CS, Tsai CR, Chang TK, Wang CJ. The neurological evolution of Pearson syndrome: Case report and literature review. Eur J Paediatr Neurol. 2007 Apr 13. [Medline].
Momont AC, Trobe JD. Transient corneal edema and left hemisphere dysfunction in pearson syndrome. J Neuroophthalmol. 2009 Jun. 29(2):158-9. [Medline].
Crippa BL, Leon E, Calhoun A, Lowichik A, Pasquali M, Longo N. Biochemical abnormalities in Pearson syndrome. Am J Med Genet A. 2015 Mar. 167A (3):621-8. [Medline].
Panda D, Gupta N, Gupta R, Bakhshi S. Pediatric myelodysplastic syndrome with cytoplasmic vacuolation in myeloid precursors. J Pediatr Hematol Oncol. 2011 Jan. 33(1):59-61. [Medline].
Ozbek N, Derbent M, Olcay L, Yilmaz Z, Tokel K. Dysplastic changes in the peripheral blood of children with microdeletion 22q11.2. Am J Hematol. 2004 Oct. 77(2):126-31. [Medline].
Angotti LB, Post GR, Robinson NS, et al. Pancytopenia with myelodysplasia due to copper deficiency. Pediatr Blood Cancer. 2008 Nov. 51(5):693-5. [Medline].
Gibson KM, Bennett MJ, Mize CE, et al. 3-Methylglutaconic aciduria associated with Pearson syndrome and respiratory chain defects. J Pediatr. 1992 Dec. 121(6):940-2. [Medline].
Baertling F, Meissner T, Troeger A, Pillekamp F, Mayatepek E, Laws HJ, et al. Granulocyte colony stimulating factor for treatment of neutropenia-associated infection in Pearson syndrome. Klin Padiatr. 2014 May. 226(3):190-1. [Medline].
Faraci M, Cuzzubbo D, Micalizzi C, et al. Allogeneic bone marrow transplantation for Pearson's syndrome. Bone Marrow Transplant. 2007 May. 39(9):563-5. [Medline].
Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006 May. 117(5):1519-31. [Medline].